Get started
Author

Caroline Bumb

Observed name: C Bumb
OpenAlex ID: A5058477367
Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
2013 · Shunqiang Li, Dong Shen, et al. · Cell Reports · 628
PDF
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
2017 · Cynthia X. Ma, Feng Gao, et al. · Clinical Cancer Research · 366
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
2017 · Cynthia X. Ma, Ron Bose, et al. · Clinical Cancer Research · 192
Body mass index, diabetes, and triple-negative breast cancer prognosis
2014 · Sarah Tait, Jose M. Pacheco, et al. · Breast Cancer Research and Treatment · 46
Racial differences in outcomes of triple-negative breast cancer
2013 · Jose M. Pacheco, Feng Gao, et al. · Breast Cancer Research and Treatment · 41
Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC).
2016 · Cynthia X. Ma, Ron Bose, et al. · Journal of Clinical Oncology · 16
Abstract CT011: Circulating tumor DNA (ctDNA) sequencing for HER2 mutation (HER2mut) screening and response monitoring to neratinib in metastatic breast cancer (MBC)
2017 · Cynthia Ma, Ron Bose, et al. · Cancer Research · 3
Racial differences in outcomes of triple-negative breast cancer.
2012 · Jose Pacheco, Feng Gao, et al. · Journal of Clinical Oncology · 3
Table S3 from Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
2023 · Cynthia X. Ma, Ron Bose, et al.
Supplementary Figures S1, S2, S3 and Tables S1, S2 from Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
2023 · Cynthia X. Ma, Ron Bose, et al.
Supplementary Table S3 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
2023 · Cynthia X. Ma, Feng Gao, et al.
Supplementary Table S3-4 caption from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
2023 · Cynthia X. Ma, Feng Gao, et al.
Supplementary Table S4 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
2023 · Cynthia X. Ma, Feng Gao, et al.
Supplementary Tables S1 and S2 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
2023 · Cynthia X. Ma, Feng Gao, et al.
Supplementary Figures S1-4 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
2023 · Cynthia X. Ma, Feng Gao, et al.
Supplementary Figures S1-4 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
2023 · Cynthia X. Ma, Feng Gao, et al.
Supplementary Figures S1, S2, S3 and Tables S1, S2 from Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
2023 · Cynthia X. Ma, Ron Bose, et al.
Table S3 from Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
2023 · Cynthia X. Ma, Ron Bose, et al.
Supplementary Table S3 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
2023 · Cynthia X. Ma, Feng Gao, et al.
Supplementary Figures S1-4 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
2023 · Cynthia X. Ma, Feng Gao, et al.
Supplementary Tables S1 and S2 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
2023 · Cynthia X. Ma, Feng Gao, et al.
Supplementary Tables S1 and S2 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
2023 · Cynthia X. Ma, Feng Gao, et al.
Supplementary Figures S1-4 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
2023 · Cynthia X. Ma, Feng Gao, et al.
Supplementary Table S3 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
2023 · Cynthia X. Ma, Feng Gao, et al.
Supplementary Table S3-4 caption from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
2023 · Cynthia X. Ma, Feng Gao, et al.
Works count: 39
Citation count: 1,295
H-index: 6
I10-index: 6
Year
Topic
Type